Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has officially announced a new board of directors and executive team, marking a new development phase focused on governance optimization and strategic upgrades [1][4] Group 1: Governance Structure - The new board consists of 11 directors, including 7 non-independent and 4 independent directors, creating a "7+4" decision-making structure that emphasizes strategic collaboration and professional governance [1][2] - Liu Dawei has been elected as the chairman, while Wang Zhentao serves as the vice chairman, ensuring a smooth transition and continuity in business development [1][2] - The independent directors bring expertise from various fields such as industry, finance, and law, enhancing the company's decision-making and risk management capabilities [2] Group 2: Strategic Implementation - The new governance team aims to establish an efficient "strategy-execution" mechanism to ensure the successful implementation of the company's strategies in marketing, R&D, and operations [2] - Kanghua Biological has completed a marketing structure transformation and will focus on reorganizing its R&D pipeline and capital operations to improve overall efficiency and market competitiveness [2][3] Group 3: Industry Development - The restructuring of governance is a critical step in implementing the company's future strategic blueprint, focusing on both "mature products" and "innovative pipelines" for further development [3] - The company plans to maintain its market position for established products while accelerating the development and commercialization of innovative vaccines, creating new growth points [3] - The new organizational structure will leverage resources from both Shanghai and Chengdu to enhance the integration of R&D, clinical, and commercialization processes [3] Group 4: Industry Benchmarking - The comprehensive upgrade of the board and executive team signifies a shift from founder-driven to a systematic and professional-driven approach [4] - This governance practice not only injects momentum into Kanghua Biological's future development but also provides a replicable model for the integration and upgrading of the Chinese biopharmaceutical industry [4]

Core Viewpoint - The establishment of a new board of directors and executive team at Kanghua Biotech marks a significant transition towards governance optimization and strategic upgrade following capital integration [3] Group 1: Board and Management Changes - Kanghua Biotech's new board consists of 11 members, including 7 non-independent directors and 4 independent directors, with Liu Dawei elected as the new chairman [1] - Wang Zhentao has been elected as vice chairman and legal representative, while Fan Changyong and Huang Hanmei have been appointed as executive vice president and vice president, respectively [1] Group 2: Share Transfer and Control Changes - In July, the former controlling shareholder Wang Zhentao and others agreed to transfer 28.47 million shares (21.91% of total shares excluding repurchased ones) to Wanke Xin Biological, totaling approximately 1.85 billion yuan [2] - Following the transfer, Wanke Xin Biological will hold 29.99% of voting rights, changing the controlling shareholder from Wang Zhentao to Wanke Xin Biological, which has no actual controller [2] Group 3: Strategic Focus and Development Plans - The new management team aims to enhance operational efficiency and market competitiveness by restructuring the R&D pipeline and capital operations, focusing on both mature products and innovative pipelines [3] - Kanghua Biotech plans to maintain its market position in established products like the rabies vaccine while accelerating the development of innovative products such as the six-valent norovirus vaccine [3] - The company intends to build a multi-platform and multi-product R&D matrix through self-research, mergers, and cooperative development [3] Group 4: Regional Collaboration and Resource Utilization - The new organizational structure will leverage resources from Shanghai and Chengdu, enhancing the integration of R&D, clinical, and commercialization processes [4] - The board will utilize the Shanghai Biomedicine M&A Fund to introduce R&D, talent, and capital advantages to Kanghua Biotech [4] Group 5: Mission and Vision - As the first controlling project of the Shanghai Biomedicine M&A Fund, Kanghua Biotech is tasked with exploring a new model for state-owned fund mergers and integrations [5]